263 related articles for article (PubMed ID: 11085534)
1. An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson SA; Myers TG; Scudiero D; Kitada S; Reed JC; Fornace AJ
Cancer Res; 2000 Nov; 60(21):6101-10. PubMed ID: 11085534
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
3. Induction of BCL2 family member MCL1 as an early response to DNA damage.
Zhan Q; Bieszczad CK; Bae I; Fornace AJ; Craig RW
Oncogene; 1997 Mar; 14(9):1031-9. PubMed ID: 9070651
[TBL] [Abstract][Full Text] [Related]
4. The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function.
Zhan Q; Alamo I; Yu K; Boise LH; Cherney B; Tosato G; O'Connor PM; Fornace AJ
Oncogene; 1996 Nov; 13(10):2287-93. PubMed ID: 8950997
[TBL] [Abstract][Full Text] [Related]
5. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
6. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents.
Srivenugopal KS; Shou J; Mullapudi SR; Lang FF; Rao JS; Ali-Osman F
Clin Cancer Res; 2001 May; 7(5):1398-409. PubMed ID: 11350911
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
9. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.
Concin N; Stimpfl M; Zeillinger C; Wolff U; Hefler L; Sedlak J; Leodolter S; Zeillinger R
Int J Oncol; 2003 Jan; 22(1):51-7. PubMed ID: 12469184
[TBL] [Abstract][Full Text] [Related]
10. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Burns TF; Bernhard EJ; El-Deiry WS
Oncogene; 2001 Aug; 20(34):4601-12. PubMed ID: 11498783
[TBL] [Abstract][Full Text] [Related]
11. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
Zhang GJ; Kimijima I; Onda M; Kanno M; Sato H; Watanabe T; Tsuchiya A; Abe R; Takenoshita S
Clin Cancer Res; 1999 Oct; 5(10):2971-7. PubMed ID: 10537367
[TBL] [Abstract][Full Text] [Related]
13. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents.
Kawakami K; Tsukuda M; Mizuno H; Nishimura G; Ishii A; Hamajima K
Anticancer Res; 1999; 19(5B):3927-32. PubMed ID: 10628333
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of expression levels of bax, bcl-2, and survivin in cancer cells during cisplatin treatment.
Ikeguchi M; Nakamura S; Kaibara N
Oncol Rep; 2002; 9(5):1121-6. PubMed ID: 12168083
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild-type p53 expression under normal growth conditions.
Liu Y; Riley LB; Bohn SA; Boice JA; Stadler PB; Sherley JL
J Cell Physiol; 1998 Nov; 177(2):364-76. PubMed ID: 9766533
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2.
Wu GS; El-Deiry WS
Clin Cancer Res; 1996 Apr; 2(4):623-33. PubMed ID: 9816212
[TBL] [Abstract][Full Text] [Related]
19. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis.
Zhan Q; Fan S; Bae I; Guillouf C; Liebermann DA; O'Connor PM; Fornace AJ
Oncogene; 1994 Dec; 9(12):3743-51. PubMed ID: 7970735
[TBL] [Abstract][Full Text] [Related]
20. High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients.
Köhler T; Würl P; Meye A; Lautenschläger C; Bartel F; Borchert S; Bache M; Schmidt H; Holzhausen HJ; Taubert H
Anticancer Res; 2002; 22(3):1553-9. PubMed ID: 12168836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
